Niraparib (MK-4827), a novel poly(ADP-ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells

Oncotarget

Volumn 5, Issue 13, 2014, Pages 5076-5086

  Bridges, Kathleen A ^a   Toniatti, Carlo ^b   Buser, Carolyn A ^c   Liu, Huifeng ^a   Buchholz, Thomas A ^a   Meyn, Raymond E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Merck Research Laboratories   (Italy)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

DNA damage; Niraparib; PARP; Radiation

Indexed keywords

DNA; HISTONE H2AX; HYDROGEN PEROXIDE; NIRAPARIB; PROTEIN P53; RAD51 PROTEIN; H2AFX PROTEIN, HUMAN; HISTONE; INDAZOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXIDIZING AGENT; PIPERIDINE DERIVATIVE; RADIOSENSITIZING AGENT;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; PROSTATE CANCER; PROSTATE CANCER CELL LINE; RADIATION DOSE; RADIOSENSITIZATION; SINGLE STRANDED DNA BREAK; BREAST TUMOR; CELL LINE; DRUG EFFECTS; FEMALE; FLUORESCENCE MICROSCOPY; GENETICS; LUNG TUMOR; MALE; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROSTATE TUMOR; RADIATION RESPONSE; TUMOR CELL LINE; TUMOR STEM CELL ASSAY;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DNA BREAKS, SINGLE-STRANDED; DNA REPAIR; FEMALE; HISTONES; HUMANS; HYDROGEN PEROXIDE; INDAZOLES; LUNG NEOPLASMS; MALE; MICROSCOPY, FLUORESCENCE; OXIDANTS; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; RAD51 RECOMBINASE; RADIATION-SENSITIZING AGENTS; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904963677     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2083     Document Type: Article

References (52)

1. Begg AC, Stewart FA and Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011; 11(4):239-253.
2. Lord CJ and Ashworth A. The DNA damage response and cancer therapy. Nature. 2012; 481(7381):287-294.
3. Ward JF. DNA damage as the cause of ionizing radiation-induced gene activation. Radiat Res. 1994; 138(1 Suppl):S85-88.
4. Mladenov E, Magin S, Soni A and Iliakis G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol. 2013; 3:113.
5. Memisoglu A and Samson L. Base excision repair in yeast and mammals. Mutat Res. 2000; 451(1-2):39-51.
6. Helleday T, Lo J, van Gent DC and Engelward BP. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst). 2007; 6(7):923-935.
7. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH and Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10(4):293-301.
8. Sandhu SK, Yap TA and de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer. 2010; 46(1):9-20.
9. Javle M and Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer. 2011; 105(8):1114-1122.
10. Lindahl T, Satoh MS, Poirier GG and Klungland A. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci. 1995; 20(10):405-411.
11. Schreiber V, Ame JC, Dolle P, Schultz I, Rinaldi B, Fraulob V, Menissier-de Murcia J and de Murcia G. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem. 2002; 277(25):23028-23036.
12. Woodhouse BC and Dianov GL. Poly ADP-ribose polymerase-1: an international molecule of mystery. DNA Repair (Amst). 2008; 7(7):1077-1086.
13. El-Khamisy SF, Masutani M, Suzuki H and Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003; 31(19):5526-5533.
14. Caldecott KW, Aoufouchi S, Johnson P and Shall S. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro. Nucleic Acids Res. 1996; 24(22):4387-4394.
15. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004; 96(1):56-67.
16. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007; 13(9):2728-2737.
17. Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, Zhu GD, Johnson EF, Rodriguez LE, Ghoreishi-Haack N, Jarvis K, Hradil VP, Colon-Lopez M, Cox BF, Klinghofer V, Penning T, et al. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res. 2008; 6(10):1621-1629.
18. Leung M, Rosen D, Fields S, Cesano A and Budman DR. Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med. 2011; 17(7-8):854-862.
19. Oleinick NL and Evans HH. Poly(ADP-ribose) and the response of cells to ionizing radiation. Radiat Res. 1985; 101(1):29-46.
20. Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res. 1985; 101(1):4-15.
21. Zwelling LA, Kerrigan D and Pommier Y. Inhibitors of poly-(adenosine diphosphoribose) synthesis slow the resealing rate of x-ray-induced DNA strand breaks. Biochem Biophys Res Commun. 1982; 104(3):897-902.
22. Cantoni O, Murray D and Meyn RE. Effect of 3-aminobenzamide on DNA strand-break rejoining and cytotoxicity in CHO cells treated with hydrogen peroxide. Biochim Biophys Acta. 1986; 867(3):135-143.
23. Annunziata CM and O'Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res. 2010; 16(18):4517-4526.
24. Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, Wedge SR and Stratford IJ. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011; 10(10):1949-1958.
25. Brock WA, Milas L, Bergh S, Lo R, Szabo C and Mason KA. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. 2004; 205(2):155-160.
26. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML and Lu B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007; 13(10):3033-3042.
27. Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, Lamartina S, Monteagudo E, Ontoria JM, Orsale MV, Palumbi MC, Pesci S, Roscilli G, Scarpelli R, Schultz-Fademrecht C, Toniatti C, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors. J Med Chem. 2009; 52(22):7170-7185.
28. Bryant HE, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, Johansson F, Fernandez S, McGlynn P and Helleday T. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009; 28(17):2601-2615.
29. Harper JV, Anderson JA and O'Neill P. Radiation induced DNA DSBs: Contribution from stalled replication forks? DNA Repair (Amst). 2010; 9(8):907-913.
30. Kling J. PARP inhibitors blaze a trail in difficult-to-treat cancers. Nat Biotechnol. 2009; 27(9):784-786.
31. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S and Pommier Y. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-5599.
32. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA, Jr., Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C and Halazonetis TD. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005; 434(7035):907-913.
33. Liu SK, Coackley C, Krause M, Jalali F, Chan N and Bristow RG. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol. 2008; 88(2):258-268.
34. Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, Wang L, El-Rayes B and Shu HK. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys. 2013; 86(3):469-476.
35. Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JC, Kirkby KJ and Kirkby NF. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol. 2013; 8:65.
36. Shunkwiler L, Ferris G and Kunos C. Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair. Int J Mol Sci. 2013; 14(2):3773-3785.
37. Barreto-Andrade JC, Efimova EV, Mauceri HJ, Beckett MA, Sutton HG, Darga TE, Vokes EE, Posner MC, Kron SJ and Weichselbaum RR. Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther. 2011; 10(7):1185-1193.
38. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, Zhang J, Slusher BS, Chakravarti A, Tofilon PJ and Camphausen K. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res. 2009; 15(2):607-612.
39. Mueller S, Bhargava S, Molinaro AM, Yang X, Kolkowitz I, Olow A, Wehmeijer N, Orbach S, Chen J, Matthay KK and Haas-Kogan DA. Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res. 2013; 33(3):755-762.
40. Powell C, Mikropoulos C, Kaye SB, Nutting CM, Bhide SA, Newbold K and Harrington KJ. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev. 2010; 36(7):566-575.
41. Godon C, Cordelieres FP, Biard D, Giocanti N, Megnin-Chanet F, Hall J and Favaudon V. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res. 2008; 36(13):4454-4464.
42. Dungey FA, Loser DA and Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys. 2008; 72(4):1188-1197.
43. Rothkamm K, Kruger I, Thompson LH and Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol. 2003; 23(16):5706-5715.
44. Taylor WR and Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001; 20(15):1803-1815.
45. Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA and Meyn RE. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 2011; 17(17):5638-5648.
46. Olive PL and Johnston PJ. DNA damage from oxidants: influence of lesion complexity and chromatin organization. Oncol Res. 1997; 9(6-7):287-294.
47. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P and Jonkers J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008; 105(44):17079-17084.
48. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH and de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-134.
49. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ and Curtin NJ. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011; 103(4):334-346.
50. Wang L, Mason KA, Ang KK, Buchholz T, Valdecanas D, Mathur A, Buser-Doepner C, Toniatti C and Milas L. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012; 30(6):2113-2120.
51. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013; 14(9):882-892.
52. Garber K. PARP inhibitors bounce back. Nat Rev Drug Discov. 2013; 12(10):725-727.